Pharmacologic inhibition of the δ isoform of phosphatidylinositol 3-kinase (PI3Kδ) reduces proliferation, migration, and survival of the malignant B-cell leukemia and lymphoma cells. The novel orally active PI3Kδ inhibitor linperlisib has shown a notable efficacy in B-cell lymphomas, especially for a FL subgroup, in a previous phase I study. In this phase II trial, Wang and colleagues report that linperlisib demonstrated compelling efficacy and was generally well tolerated in the treatment of relapsed or refractory FL patients after two or more prior systemic therapies.

Enfortumab vedotin (EV) releases a cytotoxic agent into the urothelial cancer (UC) cell via binding to the surface protein NECTIN-4. Although EV is approved in the metastatic disease stage, the NECTIN-4 expression in metastatic UC tissue is insufficiently studied. Here, Klümper and colleagues demonstrate that NECTIN-4 expression decreases substantially during metastatic evolution and is absent in more than one-third of metastases. Further, loss of membranous NECTIN-4...

You do not currently have access to this content.